Stay updated on Nivolumab and Axitinib in RCC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Axitinib in RCC Clinical Trial page.

Latest updates to the Nivolumab and Axitinib in RCC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAn administrative update adds a new revision tag (v3.4.2) and removes older notices (lapse in government funding notice and v3.4.1), with no impact on study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check20 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH Clinical Center status at the top of the page. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedShow glossary option added; capitalization tweaks to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'; and the revision version updated to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 replaces v3.3.3 in the study documents section, with no changes to core study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedLocations section consolidated under a single Locations heading, listing Maryland, New York, and Pennsylvania. Previous separate subsections for Maryland Locations, New York Locations, and Pennsylvania Locations were removed.SummaryDifference0.4%

- Check91 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Nivolumab and Axitinib in RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Axitinib in RCC Clinical Trial page.